ClinicalTrials.gg
Active, not recruitingNCT03888105ELM-2Updated Jul 31, 2026

A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies

A Phase 2 interventional study of Odronextamab in B-cell Non-Hodgkin Lymphoma (B-NHL), sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 119 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
515
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 283 studies in Lymphoma, B-Cell with a site in China — 125 open to participants now, 146 under way, 9 of them phase 3. Lymphoma, B-Cell · China.

Enrollment
10th of 273
515 · median 30
Started
2019
with 23 others
Phase 2
51 of 283
23 open now
Primary completion
2026-06
later than 46 of 145 live
Registered
57th of 283
by date

Among the 283 studies in Lymphoma, B-Cell with a site in China, this one is the 10th largest by enrollment of the 273 interventional ones that give a count, is one of 24 that started in 2019, is one of 51 in phase 2, reaches primary completion later than 46 of the 145 other live ones, and was the 57th registered.

Lymphoma, B-Cell

886 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

125 of the 283 studies in Lymphoma, B-Cell with a site in China are open now. Recruiting first, the newest first:

120 more — sign in →

All 125 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 208 Lymphoma, B-Cell studies recruiting now, 128 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 283 studies in Lymphoma, B-Cell with a site in China, or all of them as a file.
02

Study summary

This study is researching an investigational drug, odronextamab, in adult patients B-cell non-Hodgkin's lymphoma (B-NHL).

The main purpose of this study is to assess the effectiveness of odronextamab in destroying cancer cells and to learn more about the safety of odronextamab.

The study is looking at several other research questions, including:

  • To see if odronextamab works to destroy cancer cells
  • Side effects that may be experienced by people taking odronextamab
  • How odronextamab works in the body
  • How much odronextamab is present in the blood
03

Conditions studied

  • B-cell Non-Hodgkin Lymphoma (B-NHL)

Keywords

  • Relapsed B-NHL
  • Refractory B-NHL
  • NHL
  • Follicular lymphoma (FL)
  • Diffuse large B-cell lymphoma (DLBCL)
  • Mantle cell lymphoma (MCL)
  • Marginal zone lymphoma (MZL)
  • bispecific antibody
  • CD20
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. For the FL grade 1-3a cohort only: Central histopathologic confirmation of the FL Grade 1 to 3a diagnosis must be obtained before study enrollment. Patients with FL grade 3b are ineligible for this cohort but may be included in the "other B-NHL" cohort. Follicular lymphoma subtyping is based on the World Health Organization (WHO) classification (Swerdlow, 2017)
  2. Disease-specific cohorts:

    Patients should in the judgment of the investigator require systemic therapy for lymphoma at the time of study enrollment

    • FL grade 1-3a cohort: Patients with FL grade 1-3a that has after or is refractory to at least 2 , as defined in the protocol
    • DLBCL cohort: Patients with DLBCL that has relapsed after or is refractory to at least 2 prior lines of systemic therapy as defined in the protocol
    • MCL after BTK inhibitor therapy cohort: Patients with MCL who have relapsed or refractory disease to at least one prior line of systemic therapy and had prior treatment with a Bruton's tyrosine kinase (BTK) inhibitor
    • MZL cohort: Patients with MZL that have relapsed or is refractory to at least 2 prior lines of systemic therapy
    • Other B-NHL cohort: Patients with B-NHL other than FL grade 1-3a, DLBCL, MCL, or MZL that has relapsed after or is refractory to at least 2 prior lines of systemic therapy as defined in the protocol. New enrollment stopped for patients with Burkitt lymphoma and Burkitt-like lymphoma.
  3. on cross sectional imaging as defined in the protocol documented by diagnostic imaging (computed tomography (CT), or magnetic resonance imaging (MRI)
  4. (ECOG) performance status 0 or 1
  5. Adequate bone marrow, hepatic, and renal function as defined in the protocol

Key Exclusion Criteria:

  1. Primary central nervous system (CNS) lymphoma or known involvement by non-primary CNS Non-Hodgkin Lymphoma (NHL) (suspected CNS lymphoma should be evaluated by lumbar puncture, as appropriate, in addition to the mandatory head CT or MRI)
  2. Treatment with any systemic anti-lymphoma therapy within 5 half-lives or within 28 days prior to first administration of study drug, whichever is shorter
  3. History of stem cell transplantation, up to 12 months prior to first administration of study drug. The presence of acute or chronic (GVHD) will also be an exclusion
  4. Continuous systemic treatment with more than 10 mg per day of prednisone or anti-inflammatory equivalent within 72 hours of start of study drug
  5. History of neurodegenerative condition or CNS movement disorder. Patients with a history of seizure within 12 months prior to study enrollment are excluded
  6. Another except B-NHL in the past 5 years, with the exception of non-melanoma skin cancer that has undergone potentially curative therapy or in situ cervical carcinoma, or any other tumor that has been deemed to be effectively treated with definitive local control and with curative intent
  7. Uncontrolled infection with (HIV), or infection; cytomegalovirus (CMV) infection as noted by detectable levels on a blood polymerase chain reaction (PCR) assay as defined in the protocol or other uncontrolled infections
  8. Known to both allopurinol and rasburicase
  9. Prior treatment with an anti-CD20 x anti-CD3 bispecific therapy

Note: Other protocol-defined Inclusion/Exclusion criteria apply

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
515 participants (actual)

Study arms

  • Experimental
    FL

    Follicular lymphoma grade 1-3a cohort

    Drug: Odronextamab

  • Experimental
    DLBCL

    Diffuse large B-cell lymphoma cohort

    Drug: Odronextamab

  • Experimental
    MCL

    Mantle Cell Lymphoma cohort

    Drug: Odronextamab

  • Experimental
    MZL

    Marginal Zone Lymphoma cohort

    Drug: Odronextamab

  • Experimental
    Other B-NHL

    Other B-cell non-Hodgkin lymphoma cohort (excluding FL Grade 1-3a, DLBCL, MCL, MZL, Waldenström macroglobulinemia \[WM\]); Patients with a current diagnosis of mixed histology of B-NHL with an aggressive component (such as concurrent FL and DLBCL) will be allowed

    Drug: Odronextamab

Interventions

  • Administered by intravenous (IV) infusion

    Also known as: REGN1979

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR), as assessed by independent central review

    FL grade 1-3a/MZL

    Time frame: Up to 52 weeks of study treatment

  2. ORR, as assessed by independent central review

    DLBCL/MCL/Other B-NHL

    Time frame: Up to 36 weeks of study treatment

Secondary outcomes

  1. ORR, as assessed by the local investigator

    FL/MZL

    Time frame: Up to 52 weeks of study treatment

  2. ORR, as assessed by the local investigator

    DLBCL/MCL/Other B-NHL

    Time frame: Up to 36 weeks of study treatment

  3. Complete Response (CR) Rate, as assessed by the local investigator

    FL grade 1-3a/MZL

    Time frame: Up to 52 weeks of study treatment

  4. CR rate, as assessed by independent central review

    FL grade 1-3a/MZL

    Time frame: Up to 52 weeks of study treatment

  5. CR rate, as assessed by the local investigator

    DLBCL/MCL/Other B-NHL

    Time frame: Up to 36 weeks of study treatment

  6. CR rate, as assessed by independent central review

    DLBCL/MCL/Other B-NHL

    Time frame: Up to 36 weeks of study treatment

  7. Progression-Free Survival (PFS), as assessed by independent central review

    Time frame: Approximately 194 weeks following the first dose

  8. PFS, as assessed by the local investigator

    Time frame: Approximately 194 weeks following the first dose

  9. Overall Survival (OS)

    Time frame: Approximately 194 weeks following the first dose

  10. Duration Of Response (DOR), as assessed by independent central review

    Time frame: Approximately 194 weeks following the first dose

  11. DOR, as assessed by the local investigator

    Time frame: Approximately 194 weeks following the first dose

  12. Disease Control Rate (DCR), as assessed by independent central review

    FL grade 1-3a/MZL

    Time frame: Up to 52 weeks of study treatment

  13. DCR, as assessed by the local investigator

    FL grade 1-3a/MZL

    Time frame: Up to 52 weeks of study treatment

  14. DCR, as assessed by independent central review

    DLBCL/MCL/Other B-NHL

    Time frame: Up to 36 weeks of study treatment

  15. DCR, as assessed by the local investigator

    DLBCL/MCL/Other B-NHL

    Time frame: Up to 36 weeks of study treatment

  16. Incidence and severity of Treatment Emergent Adverse Events (TEAEs)

    Time frame: Approximately 194 weeks following the first dose

  17. Concentration of odronextamab

    End of infusion \[EOI\]; Concentration at a specified time t \[Ct\])

    Time frame: 12 weeks following end of treatment

  18. Incidence of Anti-Drug Antibodies (ADA) to odronextamab over time

    Time frame: 12 weeks following end of treatment

  19. Titer of anti-drug antibodies to odronextamab over time

    Time frame: 12 weeks following end of treatment

  20. Incidence of Neutralizing antibodies (Nab) to odronextamab over time

    Time frame: 12 weeks following end of treatment

  21. Changes in scores of patient-reported outcomes as measured by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Cancer-30 (EORTC-QLQ-C30)

    The EORTC QLQ-C30 is a self-reported, 30-item generic questionnaire developed to assess 15 domains: global health status scale, five functional scales (physical, role, emotional, cognitive, and social functioning) and nine symptom scales (fatigue, nausea, vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties).

    Time frame: Approximately 194 weeks following the first dose

  22. Changes in scores of patient-reported outcomes as measured by Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym)

    Composed of the FACT-G plus the 15-item Lymphoma Subscale (LymS).

    Time frame: Approximately 194 weeks following the first dose

  23. Changes in scores of patient-reported outcomes as measured by EuroQol-5 Dimensions-3 Levels (EQ-5D-3L)

    The EQ-5D-3L is a standardized instrument for use as a measure of health outcome. It is a health questionnaire that consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems.

    Time frame: Approximately 194 weeks following the first dose

07

Study locations

119 sites

Showing the first 100 of 119 sites across 14 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Villasboas JC, Poon M, Tani M, Jimenez-Ubieto A, Tessoulin B, Warwick L, Brown D, Namuduri M, Lin C, Delwart V, Jagadeesh D. Odronextamab in people with relapsed or refractory follicular lymphoma: plain language summary of the ELM-2 study. Future Oncol. 2026 Mar;22(6):643-658. doi: 10.1080/14796694.2026.2628111. Epub 2026 Mar 1. PubMed 41766170 ↗
  • Arnason JE, Matasar M, Luminari S, Tucker D, Sun D, Tao W, Zhu YO, Kundu K, Gupta NT, Leary A, Jankovic V, Ambati S, Mohamed H, Chaudhry A, Brouwer-Visser J. Early clearance of circulating tumor DNA and association with odronextamab response in relapsed/refractory FL and DLBCL. Blood Adv. 2025 Dec 9;9(23):6130-6140. doi: 10.1182/bloodadvances.2025016332. PubMed 40902079 ↗
  • Danilov AV, Kambhampati Thiruvengadam S, Linton K, Cumings K, Chirikov V, Mutebi A, Bains Chawla S, Chhibber A, Rivas Navarro F, Marques Goncalves F, Wang A, Ding Z, Alshreef A, Favaro E, Hoehn D, Sureda A. Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma. Blood Adv. 2025 Aug 12;9(15):3754-3765. doi: 10.1182/bloodadvances.2024015274. PubMed 40472301 ↗
  • Kim WS, Kim TM, Cho SG, Jarque I, Iskierka-Jazdzewska E, Poon LM, Prince HM, Zhang H, Cao J, Zhang M, Tessoulin B, Oh SY, Lim F, Carpio C, Tan TD, Ayyappan S, Gutierrez A, Cai J, Ufkin M, Shariff S, Brouwer-Visser J, Chaudhry A, Mohamed H, Ambati S, Walewski J; ELM-2 Investigators. Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial. Nat Cancer. 2025 Mar;6(3):528-539. doi: 10.1038/s43018-025-00921-6. Epub 2025 Mar 17. PubMed 40097657 ↗

Related links

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Jun 2026, 79 months.

Of 120 phase 2 interventional studies under Lymphoma, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 73. This study's 79 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2019
First posted
Mar 25, 2019
StartActual
Nov 13, 2019
Primary completionActual
Jun 17, 2026
CompletionEst.
Dec 15, 2028
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03888105
Responsible party
Sponsor
First posted
Mar 25, 2019
Start date
Nov 13, 2019
Primary completion
Jun 17, 2026
Completion
Dec 15, 2028 (estimated)
Last update
Jul 31, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Odronextamab

Start the discussion